ATOS

Over the past six months, Atossa completed a Type C meeting with the FDA and received Rare Pediatric Disease Designation and Orphan Drug Designation for (Z)-Endoxifen. The company issued a letter to shareholders highlighting accomplishments and the 2026 outlook, with the stock price reaching a 52-week low. Atossa reported its Fourth Quarter and Year-End 2025 financial results, announcing it would not proceed with advancing (Z)-Endoxifen in metastatic breast cancer. Pre-clinical data for (Z)-Endoxifen in DMD was presented at a conference. Phase 2 trial results for (Z)-Endoxifen were published, and the company received FDA Rare Pediatric Disease Designation for McCune-Albright Syndrome. Atossa reported its First Quarter 2026 financial results, with the stock price declining and a reverse stock split mentioned.